Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
- 16 October 2008
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 26 (44), 5654-5661
- https://doi.org/10.1016/j.vaccine.2008.07.098
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in FranceInternational Journal of Technology Assessment in Health Care, 2008
- Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluationVaccine, 2007
- Cost–utility analysis of vaccination against HPV in IsraelVaccine, 2007
- Cost-effectiveness of HPV 16, 18 vaccination in BrazilVaccine, 2007
- Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The NetherlandsVaccine, 2007
- The potential cost-effectiveness of prophylactic human papillomavirus vaccines in CanadaVaccine, 2007
- A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening ProgramSexual Health, 2007
- Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lostInternational Journal of Cancer, 2004
- Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening ProgramsJAMA, 2003
- Cost Effectiveness of a Potential Vaccine forHuman papillomavirusEmerging Infectious Diseases, 2003